Nightstar Files SEC Paperwork for Initial Public Offering

September 1, 2017: By Jon Swedien

Nightstar TherapeuticsNightstar Therapeutics Limited has filed a registration statement with the US Securities and Exchange Commission for a proposed initial public offering in the US of its American depositary shares (ADSs) representing ordinary shares, the company announced Aug. 31.

Nightstar is a clinical-stage gene therapy company focused on novel one-time treatments for patients with rare inherited retinal diseases that would otherwise progress to blindness.

All shares to be sold in the offering will be offered by Nightstar, the company said.

The number of shares and price range have not been set, Nightstar said.

The company has applied to list its shares on the NASDAQ Global Market under the ticker symbol “NITE.”

Nightstar expects its lead product candidate, NSR-REP1, to begin a Phase III trial for choroideremia in the the first half of 2018.

The company also has an ongoing Phase I/II clinical trial for NSR-RPGR, a proposed treatment for X-linked retinitis pigmentosa.

In addition, Nightstar has a Phase I/II clinical trial planned for late 2018 for a gene therapy candidate for an inherited form of macular dystrophy.

In June, Nightstar raised $45 million in a Series C financing.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

FDA Advisory Panel to Review Aerie’s Rhopressa in October

Johnson & Johnson Vision Acquires Online Contact Lens Business Sightbox

Novartis Returns OUS Rights for Jetrea to ThromboGenics

Eyevance Licenses Zerviate from Nicox for US Commercialization

Two Eye Projects Fail to Make Final Round for $100M Grant

Ophthotech Begins Phase IIa Trial for Zimura in Wet AMD

Graybug Vision Begins Phase I/II Trial for Candidate in Wet AMD

BioTime Receives $1.56 Million NIH Grant to Advance OpRegen for Dry AMD

FDA Approves Mvasi, a Biosimilar of Avastin Co-developed by Amgen, Allergan

Carl Zeiss Meditec Launches Zeiss Clarus 500 Ultra-Widefield Fundus Imaging System in US

Imprimis Appeals to Public Sentiment in Fiery Response to Allergan Lawsuit

Roche’s Lampalizumab Fails in Phase III Study in Geographic Atrophy

Aldeyra Reports Positive Phase IIa Results for Dry Eye Candidate ADX-102

US Denies Coherus’ Petitions Challenging AbbVie’s Patent for Humira

Ocular Therapeutix Names Michael Goldstein, MD, Chief Medical Officer

PhysIOL Agrees to Acquire Majority Stake in Italian Optikon

Rayner Creates US Subsidiary in New York

Inotek to Merge with Gene Therapy Startup Rocket

Allergan Agrees to $13.75 Million Deal with Tribe to Protect Restasis Patents

Ellex to Boost Production of iTrack Microcatheters to 50 Thousand a Year

Coming soon

2017 Retinal Pharmaceuticals and Biologics Report: A Global Market Analysis for 2016 to 2022